Sitafloxacin monohydrate
Based on 7 publication(s) in Google Scholar
Sitafloxacin (DU6859a) monohydrate is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin monohydrate shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin monohydrate can be used for the research of respiratory tract infection and urinary tract infection.
For research use only. We do not sell to patients.
- CAS No.: 163253-37-0
- Formula: C19H20ClF2N3O4
- Molecular Weight:427.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Sitafloxacin monohydrate
More- Toxicol Sci. 2026 Mar 25:kfag039. [Abstract]
- Antimicrob Resist Infect Control. 2019 Feb 15:8:40. [Abstract]
- Antimicrob Agents Chemother. 2026 Jul 2.
- Infect Drug Resist. 2019 Jan 31:12:345-358. [Abstract]
- Curr Microbiol. 2021 Dec 14;79(1):12. [Abstract]
- PLoS One. 2019 Mar 27;14(3):e0213868. [Abstract]
- bioRxiv. 2024 Nov 06.
All Antibiotic Isoforms
More
Biological Activity
Description
IC50 & Target
|
Quinolone |
In Vitro
Sitafloxacin (DU6859a) monohydrate shows antibacterial activities with MIC of 0.03, 0.12, 0.06 mg/L for wild-type ATCC 49619, gyrA mutant SP39, parC mutant 1026523 streptococcus pneumoniae stran, respectively[1].
Sitafloxacin (DU6859a) monohydrate shows antibacterial activities for quinolone-susceptible strains of streptococcus pneumoniae with MIC of 0.03, 0.03 mg/L for EG 00093 and EG 00218 strain, respectively[1].
Sitafloxacin (DU6859a) monohydrate shows inhibition for DNA gyrase and topoisomerase IV (TopoIV) with >IC50s of 4.38, 3.12 mg/L, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c female mice[2]
-
Dosage:12.5, 25, 50 and 100 mg/kg
-
Administration:Oral gavage; daily, for 4 weeks
-
Result:Inhibits the growth of Mycobacterium ulcerans and the M. ulcerans cells.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 163253-37-0
-
Molecular Weight 427.83
-
Formula C19H20ClF2N3O4
-
SMILES
O=C(C1=CN([C@H]2[C@@H](F)C2)C3=C(C=C(F)C(N(C[C@H]4N)CC54CC5)=C3Cl)C1=O)O.O
-
Synonyms
DU6859a monohydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Toxicol Sci
In vitro and preclinical assessment of drug interactions between fluoroquinolones and a nonsteroidal antiinflammatory drug predicting risk of seizure. [Abstract]2026 Mar 25:kfag039. PMID: 41883118 -
Antimicrob Resist Infect Control
Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. [Abstract]2019 Feb 15:8:40. PMID: 30815255 -
-
Infect Drug Resist
Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. [Abstract]2019 Jan 31:12:345-358. PMID: 30774400 -
Curr Microbiol
Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa. [Abstract]2021 Dec 14;79(1):12. PMID: 34905092 -
PLoS One
Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. [Abstract]2019 Mar 27;14(3):e0213868. PMID: 30917150 -
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Anaerobic Bacterial Culture
Anaerobic bacterial culture detects viable bacteria that can grow under oxygen-depleted conditions; the readout is visible colony formation or broth turbidity after incubation in a chamber, jar, pouch, bag, or roll-tube system that maintains anaerobiosis. Oxygen control is central to the method because recovery depends on limiting oxygen exposure during collection, transport, inoculation, and incubation.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
References
[1]. Okumura R, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. [Content Brief]
[2]. Dhople AM, et al. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice. J Chemother. 2003 Feb;15(1):47-52. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)